enGene Therapeutics Inc.
ENGNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.54M in total; no superinvestor holds it.
Other share classesENGN
13F holders, Q2 2024
Institutional positions in enGene Therapeutics Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- 0 vs. Q1 2024
- Shares held
- 4.91M
- −592.5K (−10.8%) vs. Q1 2024
- Total value
- $6.54M
- −$22.1M (−77.2%) vs. Q1 2024
- New holders
- 2
- 1 more added
- Sold out
- 2
- 6 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENGNW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 11 | $1.54M |
| Q1 2026 | 11 | $12.9M |
| Q4 2025 | 14 | $13.9M |
| Q3 2025 | 17 | $3.29M |
| Q2 2025 | 15 | $3.70M |
| Q1 2025 | 14 | $2.91M |
| Q4 2024 | 15 | $4.02M |
| Q3 2024 | 14 | $9.20M |
| Q2 2024 | 16 | $6.54M |
| Q1 2024 | 16 | $28.6M |
| Q4 2023 | 25 | $6.26M |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding enGene Therapeutics Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FCPM III Services B.V. | 2,878,148 | $3.42M | 0.51% | 00.0% | Unchanged |
| BVF Inc | 945,402 | $1.31M | 0.04% | 00.0% | Unchanged |
| Blue Owl Capital Holdings LP | 51,177 | $608.3K | 0.17% | −460,000−90.0% | Reduced |
| Omega Fund Management, LLC | 321,502 | $382.6K | 0.28% | −39,401−10.9% | Reduced |
| Saba Capital Management, L.P. | 192,334 | $248.1K | 0.01% | −1,629−0.8% | Reduced |
| Calamos Advisors LLC | 150,000 | $208.5K | 0.00% | 00.0% | Unchanged |
| D. E. Shaw & Co., Inc. | 104,622 | $145.4K | 0.00% | 00.0% | Unchanged |
| Tenor Capital Management Co., L.P. | 55,243 | $65.7K | 0.00% | −9,757−15.0% | Reduced |
| Whitebox Advisors LLC | 33,333 | $39.7K | 0.00% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 28,197 | $33.6K | 0.00% | +15,507+122.2% | Added |
| State of Wisconsin Investment Board | 23,570 | $32.8K | 0.00% | 00.0% | Unchanged |
| CSS LLC | 16,895 | $20.1K | 0.00% | −3,105−15.5% | Reduced |
| UBS Group AG | 12,160 | $14.5K | 0.00% | +12,160 | New |
| Clear Street LLC | 200 | $238 | 0.00% | −4,800−96.0% | Reduced |
| Bank of America Corp | 200 | $238 | 0.00% | +200 | New |
| Polar Asset Management Partners Inc. | 97,391 | $0 | 0.00% | 00.0% | Unchanged |
| Atalaya Capital Management LP | 0 | $0 | 0.00% | −66,666−100.0% | Sold out |
| Cowen and Company, LLC | 0 | $0 | 0.00% | −34,998−100.0% | Sold out |